共 92 条
[1]
Crouse J.R. III, Allan M.C., Elam M.B., Clinical manifestation of atherosclerotic peripheral arterial disease and the role of cilostazol in treatment of intermittent claudication, J. Clin. Pharmacol., 42, pp. 1291-1298, (2002)
[2]
Olin J.W., Management of patients with intermittent claudication, Int. J. Clin. Pract., 56, 9, pp. 687-693, (2002)
[3]
Fernandez B.B. Jr., A rational approach to diagnosis and treatment of intermittent claudication, Am. J. Med. Sci., 323, 5, pp. 244-251, (2002)
[4]
Donnelly R., Assessment and management of intermittent claudication: Importance of secondary prevention, Int. J. Clin. Pract., SUPPL. 119, pp. 2-9, (2001)
[5]
Management of peripheral arterial disease (PAD), J. Vasc. Surg., 31, 1 SUPPL. 1, (2000)
[6]
Criqui M.H., Fronek A., Barrett-Connor E., Et al., The prevalence of peripheral arterial disease in a defined population, Circulation, 71, pp. 510-515, (1985)
[7]
(2003)
[8]
Okuda Y., Kimura Y., Yamashita K., Cilostazol, Cardiovasc. Drug Rev., 11, 4, pp. 451-465, (1993)
[9]
Liu Y., Shakur Y., Yoshitake M., Et al., Cilostazol (Pletal®): A dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake, Cardiovasc. Drug Rev., 19, 4, pp. 369-386, (2001)
[10]
Reilly M.P., Mohler E.R. III, Cilostazol: Treatment of intermittent claudication, Ann. Pharmacother., 35, 1, pp. 48-56, (2001)